Anna Skwarska

9PUBLICATIONS
73CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Aerospace engineering not elsewhere classifiedHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 29, 2026
Specific F1 ATP synthase inhibition delivers transient mitochondrial stress for selective targeting of acute myeloid leukemia.

|Jul 23, 2026
LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical Models.

|Feb 05, 2026
TP53 loss traps AML in XPO7-NPAT nuclear transport fraud.

Anna Skwarska, Marina Konopleva

|Mar 31, 2025
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.

Zhe Wang, Anna Skwarska, Gowri Poigaialwar

|Oct 12, 2023
BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs.

Anna Skwarska, Marina Konopleva

|Jan 23, 2023
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.

Hannah Beird, C Cameron Yin, Joseph D Khoury

Pageof 2

Frequent Collaborators

6 joint publications

Marina Y Konopleva

2 joint publications

Magdalena Niemira

2 joint publications

Adam Krętowski

2 joint publications

Naveen Pemmaraju